We are focused on developing the next generation of best-in-class biologics, with an emphasis on multispecific antibodies and their derivatives. Invenra's proprietary technologies combine our highly developable B-Body™ bispecific platform with high throughput functional screening, enabling the optimization of unprecedented numbers of bispecific antibodies in phenotypic assays. Invenra has a pipeline of immuno-oncology bispecific antibodies that are currently in preclinical studies.

We are focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. I have helped guide the development of Invenra's proprietary technology combining cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies in phenotypic assays.

EXIX Bio offers three cell-free expression mixes covering a range of applications and outrank their competitors in efficiency and cost. The S-Mix is designed for standard expression of proteins from plasmid and linear templates. The C-Mix (coming soon) is designed for complex harder-to-fold proteins and allows for user optimization of redox and chaperones. The A-Mix (coming soon) is tailored to antibody production, and is capable of producing over 100 µg/mL of full-length IgG antibodies.See exixbiollc.com for more information

PhD Candidate in the Molecular and Cellular Pharmacology Program. I work in the laboratory of Richard Burgess in the McArdle Laboratories for Cancer Research. My dissertation title is "Studying the E. coli Sigma Factors Interaction with Core RNA Polymerase using Lumiscence Resonance Energy Transfer".

Undergraduate research assistant in the laboratory of Dr. Chris Bradfield